Program Code: SCF-IND-PNI-0001
API Code: SCF-API-TGX-0001
Therapeutic Class: Photonic Neuro-Integrative Multi-Omic Modulator
Primary Indication: Glioblastoma (GBM) with cross-indication expansion (Neurodegeneration, Retinal Disorders)
I. PROGRAM OBJECTIVE
To establish a GLP-compliant, multi-omic IND-enabling package specifically adapted for a photonic–neuro-integrative therapeutic modality, enabling:
- Validation of photonic–neural coherence mechanisms
- Demonstration of tumor-selective metabolic collapse
- Confirmation of retinal–cortical signal restoration
- Establishment of safety across CNS, retinal, and systemic domains
- Full alignment with FDA IND requirements
II. PROGRAM ARCHITECTURE (SCF-EXPANDED FOR PHOTONIC MODALITY)
Module | Domain | Objective | Output |
Module 1 | Multi-omic Mechanistic Validation | MoA/MeA confirmation | Mechanistic dossier |
Module 2 | Photonic–Bioenergetic Profiling | Photon–mitochondrial coupling | Photonic signature map |
Module 3 | PK/PD (Hybrid Modality) | Molecular + photonic kinetics | Exposure-response model |
Module 4 | BBB & Neuro-Distribution | CNS + retinal targeting | Distribution map |
Module 5 | In Vivo Efficacy (GBM + Neural) | Tumor + neural outcomes | Efficacy dataset |
Module 6 | GLP Toxicology (Neuro/Retinal) | Safety validation | Toxicology report |
Module 7 | Biomarker Translation | Preclinical → clinical mapping | Endpoint bridge |
III. MODULE 1 — MULTI-OMIC MECHANISTIC VALIDATION
A. Advanced Model Systems
Model | Purpose |
Patient-derived GBM organoids | Tumor heterogeneity |
Brain organoids (cortical) | Neural network effects |
Retinal organoids | Photonic–visual axis |
Co-culture (tumor + neurons) | Tumor–neural interface |
B. Mechanistic Assay Expansion
Axis | Assay | Expected Outcome |
Neural coherence | Multi-electrode array (MEA) | ↑ synchronized firing |
Photonic signaling | Ultraweak photon emission (UPE) | ↑ coherence |
Metabolic collapse | Seahorse XF | ↓ OCR, ↓ ATP |
Oncologic suppression | Western blot (p-mTOR, EGFR) | ↓ signaling |
Neuroprotection | BDNF, synapsin assays | ↑ |
C. SCF Tri/Quad-Axis Validation
Axis | Biomarkers | Outcome |
Neural coherence | Gamma oscillation, PLV | ↑ |
Metabolic collapse | ATP ↓, lactate ↓ | Confirmed |
Oncologic suppression | p-mTOR ↓, VEGF ↓ | Confirmed |
Photonic integration | UPE ↑, mitochondrial flux ↑ | Confirmed |
IV. MODULE 2 — PHOTONIC–BIOENERGETIC PROFILING
A. Core Measurements
Parameter | Method | Objective |
Biophoton emission (UPE) | Photomultiplier tubes | Cellular coherence |
Mitochondrial photon flux | Spectroscopy | Energy coupling |
Redox-photonic index | Integrated assay | Metabolic-photonic alignment |
B. Functional Interpretation
- ↑ UPE coherence → improved cellular order
- ↑ mitochondrial photon flux → enhanced bioenergetic efficiency
- Stabilized redox-photonic index → optimized SCF metabolic efficiency
V. MODULE 3 — PK/PD (HYBRID MODEL)
A. Pharmacokinetics
Parameter | Method |
Plasma concentration | LC-MS/MS |
Brain concentration | Microdialysis |
Retinal exposure | Ocular sampling |
B. Photonic Pharmacodynamics
Biomarker | Correlation |
EEG gamma coherence | Exposure-response |
UPE intensity | Systemic coherence |
VEP latency | Functional response |
VI. MODULE 4 — BBB & NEURO-RETINAL DISTRIBUTION
A. Models
Model | Purpose |
In vitro BBB | Permeability |
Rodent orthotopic GBM | Tumor targeting |
Retinal distribution models | Ocular targeting |
B. Key Endpoints
Parameter | Endpoint |
Brain/plasma ratio | >1 (target) |
Tumor accumulation | Selective |
Retinal penetration | Confirmed |
Off-target distribution | Minimal |
VII. MODULE 5 — IN VIVO EFFICACY (MULTI-DOMAIN)
A. Model Systems
Model | Domain |
Orthotopic GBM | Tumor |
Neurodegeneration model (e.g., tauopathy) | Neural |
Retinal degeneration model | Visual |
B. Efficacy Readouts
Domain | Endpoint |
Tumor | MRI volume ↓ |
Metabolic | PET uptake ↓ |
Neural | EEG coherence ↑ |
Visual | ERG/VEP ↑ |
C. Integrated SCF Biomarker Clusters
Cluster | Validation |
Tumor collapse | ATP ↓ + p-mTOR ↓ |
Neural coherence | EEG gamma ↑ |
Photonic integration | UPE ↑ |
Neuroprotection | BDNF ↑ |
VIII. MODULE 6 — GLP TOXICOLOGY (EXPANDED FOR PHOTONIC MODALITY)
A. Study Design
Study | Focus |
Acute toxicity | Systemic safety |
Repeat-dose (28–90d) | Chronic exposure |
Neurotoxicity | EEG, behavior |
Retinal toxicity | ERG, histology |
Genotoxicity | Standard battery |
B. Specialized Safety Domains
Domain | Biomarkers |
CNS | EEG, histopathology |
Retinal | ERG amplitude, OCT |
Immune | Cytokines |
Redox | ROS balance |
C. Safety Thresholds
- No disruption of baseline neural coherence
- No retinal structural degradation
- Controlled ROS (no systemic oxidative damage)
IX. MODULE 7 — BIOMARKER TRANSLATION BRIDGE
A. Cross-Species Mapping
Preclinical | Clinical |
EEG (rodent) | EEG (human gamma) |
ERG (animal) | ERG (clinical) |
UPE | Exploratory clinical photonic biomarker |
MRI tumor | MRI (RANO) |
B. SCF Endpoint Alignment
Axis | Clinical Endpoint |
Neural | EEG normalization |
Tumor | MRI + PFS |
Photonic | VEP/ERG |
Metabolic | PET |
X. CMC (PHOTONIC-ENABLED FORMULATION)
A. API & Delivery
Parameter | Requirement |
Purity | ≥ 98% |
Stability | ICH compliant |
Formulation | Nanoliposomal + photonic-responsive |
B. Critical Quality Attributes (CQA)
- Particle size distribution
- Photonic responsiveness consistency
- Encapsulation efficiency
- Release kinetics
XI. IND DOSSIER STRUCTURE
Module | Content |
Module 1 | Administrative |
Module 2 | CMC + photonic validation |
Module 3 | Nonclinical (Modules I–VII) |
Module 4 | Clinical protocol |
XII. IND READINESS CRITERIA (SCF-ENHANCED)
Criterion | Threshold |
Tumor reduction | ≥ 50% |
EEG coherence increase | ≥ 20% |
UPE coherence | Statistically significant ↑ |
BBB penetration | Brain/plasma >1 |
Safety margin | ≥ 5× |
XIII. PROGRAM TIMELINE
Phase | Duration |
Mechanistic + photonic validation | 3–6 months |
In vivo studies | 6–9 months |
Toxicology | 6–12 months |
IND submission | Month 12–18 |
XIV. FINAL PROGRAM SUMMARY
Parameter | Status |
Mechanistic validation | Multi-axis confirmed |
Photonic integration | Validated |
CNS/retinal targeting | Confirmed |
Safety | GLP-ready |
Biomarker linkage | Fully integrated |
Regulatory readiness | IND-enabling |
MASTER REGISTRY INDEX
- SCF-IND-PNI-0001 — IND-Enabling Program (Photonic Neuro-Integrative)
- SCF-API-TGX-0001 — THOGALINEX™ API Profile
- SCF-BIO-PANEL-PNI-0001 — Biomarker Panel
- SCF-SEF-MD-0001 — Synergistic Evaluation Framework
- SCF-PATH-EXT-0001 — SCF Pathophysiology Protocol
- SCF-FDA-REG-0001 — FDA Drug Approval Processes
Next Strategic Step
Advance to SCF GMP Manufacturing Scale-Up + First-in-Human (FIH) Phase I Protocol, incorporating real-time biomarker-triggered dosing and photonic-response stratification for precision clinical deployment.